Ready to make a difference against DR-TB? tNGS offers a powerful tool, join our webinar for expert insights on cost-effectiveness, accuracy, utility & tNGS implementation considerations.
Register: ilmn.ly/43rCUYm#drugresistance#NGS#YesWeCanEndTB#EndTB#tNGSforTB
Dr Nicole Chia a Clinical #cytogenetics expert will share her experience and the fundamental steps to consider when launching a molecular cytogenetic service or changing between #microarray platforms. Register now: ilmn.ly/3wxfHHSbit.ly/3Iry5Vl
Join our global tuberculosis expert panel for a roundtable discussion at World Conference on Lung Health 2023 #UnionConf2023 and explore the transformative impact of NGS on TB drug resistance detection #YesWeCanEndTB#EndTB
NEW 2023 Tuberculosis eBook- Sequencing methods that unravel the complexities of drug resistance. Download FREE eBook now. ilmnmkt.illumina.com/2016011…
Illumina introduces two new library prep solutions that will help build global genomic and surveillance capabilities and power impactful microbiology research. In the genome era, infectious diseases don’t have to be a disaster. #OneHealthbit.ly/3LxO0TZ
Illumina is exhibiting (booth number A05) at the PrecisionMed Exhibition and Summit 2023 in Dubai from 24-25 May! Join our session on 24 May, Samih will be speaking about Illumina's Complete Long Read Technology.
#pmes2023bit.ly/3MvIxxU
"Illumina Complete Long Reads overcomes those pain points and associated costs to make long-read #sequencing accessible and streamlined for genomic labs." – Alex Aravanis, chief technology officer and head of research and product development at Illumina. bit.ly/3lg9f2N
"We have to be mindful that after cancer treatment, kids have a much longer lifetime ahead of them, so developing precision therapies that don’t have off-target effects is much more important in pediatrics.” – Midhat Farooqi, Director of Molecular Oncology bit.ly/3ZA3dsL
Please join @Illumina on 15 April with the Singapore Society of Oncology and @AstraZeneca! Thought leaders will share their experience on the clinical utility of genomics in #precisiononcology at the Precision Oncology Diagnostics Forum. Register now bit.ly/3F1UcQW
"Now with this test, we are empowering labs in the US to unlock the most comprehensive tumor analysis from a single sample." – Kevin Keegan, VP and GM of Oncology at Illumina bit.ly/3KTSk0w
Tuberculosis (#TB) is a leading global infectious disease killer. In this webinar, 3 accomplished TB researchers will discuss how they advance the fight against TB with the use of #NGS. Join Illumina's #WorldTBday webinar on 24/3! #YesWeCanEndTBbit.ly/3Y4Q6hL
Comprehensive molecular profiling methods are enhancing actionable target discovery in pediatric cancer. Whole genome, transcriptome & methylome profiling are giving researchers an extra dimension of information for a personalized treatment plan bit.ly/3sT5aBT
The ZERO Childhood Cancer program is Australia's most comprehensive advance in delivering precision medicine to children and young people diagnosed with cancer. Learn more at ilmnmkt.illumina.com/2016010…bit.ly/3sNSjkw
Are you based in New Zealand and looking to generate pilot data? Illumina and Grafton Clinical Genomics is now awarding 1 recipient a chance to receive a 24-sample pilot project using the TSO 500 solution from Illumina. Apply Now. bit.ly/3AgjeJ1
Illumina believes in a sustainable future and is committed to supporting innovative solutions to feed the planet responsibly. Apply for the Greater Good Initiative grant. bit.ly/3Qlm3z8